Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO. Chamseddine S, et al. Among authors: duda dg. J Hepatocell Carcinoma. 2024 Mar 4;11:455-461. doi: 10.2147/JHC.S452564. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38463542 Free PMC article.
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Dogra P, et al. Among authors: duda dg. Mol Cancer. 2024 Aug 2;23(1):156. doi: 10.1186/s12943-024-02060-5. Mol Cancer. 2024. PMID: 39095771 Free PMC article.
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Mohamed YI, et al. Among authors: duda dg. Cancer Biomark. 2024;41(1):83-91. doi: 10.3233/CBM-230431. Cancer Biomark. 2024. PMID: 39269823 Free PMC article.
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.
LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO. LaPelusa M, et al. Among authors: duda dg. Oncology. 2024 Oct 18:1-8. doi: 10.1159/000541250. Online ahead of print. Oncology. 2024. PMID: 39427654 Free article.
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO. Chamseddine S, et al. Among authors: duda dg. J Immunother Precis Oncol. 2024 Nov 1;7(4):255-262. doi: 10.36401/JIPO-24-6. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524465 Free PMC article.
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Saylor PJ, Kozin SV, Matsui A, Goldberg SI, Aoki S, Shigeta K, Mamessier E, Smith MR, Michaelson MD, Lee RJ, Duda DG. Saylor PJ, et al. Among authors: duda dg. Radiother Oncol. 2024 Mar;192:110091. doi: 10.1016/j.radonc.2024.110091. Epub 2024 Jan 13. Radiother Oncol. 2024. PMID: 38224917
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Wu B, Tapadar S, Ruan Z, Sun CQ, Arnold RS, Johnston A, Olugbami JO, Arunsi U, Gaul DA, Petros JA, Kobayashi T, Duda DG, Oyelere AK. Wu B, et al. Among authors: duda dg. ACS Pharmacol Transl Sci. 2024 Sep 5;7(10):3155-3169. doi: 10.1021/acsptsci.4c00358. eCollection 2024 Oct 11. ACS Pharmacol Transl Sci. 2024. PMID: 39416967
Predictive Model of Liver Toxicity to Aid the Personalized Selection of Proton Versus Photon Therapy in Hepatocellular Carcinoma.
Chamseddine I, Kim Y, De B, Naqa IE, Duda DG, Wolfgang JA, Pursley J, Wo JY, Hong TS, Paganetti H, Koay EJ, Grassberger C. Chamseddine I, et al. Among authors: duda dg. Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):1234-1243. doi: 10.1016/j.ijrobp.2023.01.055. Epub 2023 Feb 4. Int J Radiat Oncol Biol Phys. 2023. PMID: 36739920
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Dogra P, et al. Among authors: duda dg. medRxiv [Preprint]. 2024 Mar 15:2024.03.14.24304306. doi: 10.1101/2024.03.14.24304306. medRxiv. 2024. Update in: Mol Cancer. 2024 Aug 2;23(1):156. doi: 10.1186/s12943-024-02060-5 PMID: 38559070 Free PMC article. Updated. Preprint.
252 results